Who buys srga stock?
SRGA stock was bought by a variety of institutional investors in the last quarter, including Global Trust Asset Management LLC, and Kestra Advisory Services LLC. Company insiders that have bought Surgalign stock in the last two years include Mark Stolper, Nicholas J Valeriani, Terry M Rich, Thomas Mceachin, and William Scott Durall.
What are the earnings earnings for surgalign holdings (srga)?
Surgalign Holdings, Inc. (NASDAQ:SRGA) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03.
Is surgalign (surgalign) a good value stock to buy now?
Only 32.36% of the stock of Surgalign is held by institutions. Earnings for Surgalign are expected to grow in the coming year, from ($0.44) to ($0.39) per share. The P/E ratio of Surgalign is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Will surgalign (srga) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Surgalign and other stocks. Vote “Outperform” if you believe SRGA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRGA will underperform the S&P 500 over the long term.
Is SRGA a buy?
Out of 1 analyst, 0 (0%) are recommending SRGA as a Strong Buy, 0 (0%) are recommending SRGA as a Buy, 1 (100%) are recommending SRGA as a Hold, 0 (0%) are recommending SRGA as a Sell, and 0 (0%) are recommending SRGA as a Strong Sell. What is SRGA's earnings growth forecast for 2022-2023?
Will SRGA go up?
Surgalign Holdings Inc (NASDAQ:SRGA) The 2 analysts offering 12-month price forecasts for Surgalign Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate of 30.00. The median estimate represents a +883.61% increase from the last price of 3.05.
Why did Surgalign stock drop?
Surgalign (NASDAQ:SRGA) reported Q2 FY 2021 earnings on 06-Aug-2021. The stock price fell by ~15% in reaction to earnings, a surprising and unjustified sell-off that has relegated a medical device company specializing in spine surgery and AI / machine learning digital surgery to the realm of penny stocks.
Is CSX stock a buy or sell?
CSX has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.
Is Nikon stock a good buy?
Nikon (NINOY) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Who owns SRGA stock?
Top 10 Owners of Surgalign Holdings IncStockholderStakeShares ownedThe Vanguard Group, Inc.2.29%151,602Omega Advisors, Inc.1.67%110,866Glen Capital Partners LLC1.67%110,297Mitsubishi UFJ Kokusai Asset Mana...1.60%106,2636 more rows
Is Juva life a good stock to buy?
If you are looking for stocks with good return, Juva Life Inc stock can be a bad, high-risk 1-year investment option. Juva Life Inc real time quote is equal to 0.133 USD at 2022-07-23, but your current investment may be devalued in the future.
What is a 1 for 30 reverse stock split?
The 1-for-30 reverse stock split will automatically convert 30 current shares of the Company's common stock into one share of common stock. No fractional shares will be issued in connection with the reverse stock split.
Should I buy or sell Surgalign stock right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last year. There are currently 1 hold rating and...
What is Surgalign's stock price forecast for 2022?
4 brokers have issued 12 month price targets for Surgalign's shares. Their forecasts range from $30.00 to $120.00. On average, they expect Surgalig...
How has Surgalign's stock performed in 2022?
Surgalign's stock was trading at $21.4920 at the start of the year. Since then, SRGA shares have decreased by 78.6% and is now trading at $4.60. V...
Are investors shorting Surgalign?
Surgalign saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 307,600 shares, an increase of 98...
When is Surgalign's next earnings date?
Surgalign is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Surgalign .
How were Surgalign's earnings last quarter?
Surgalign Holdings, Inc. (NASDAQ:SRGA) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($2.40) earnings per share...
When did Surgalign's stock split? How did Surgalign's stock split work?
Shares of Surgalign reverse split before market open on Tuesday, May 17th 2022. The 1-30 reverse split was announced on Tuesday, May 17th 2022. The...
What guidance has Surgalign issued on next quarter's earnings?
Surgalign updated its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of for the period. The company issued reve...
Who are Surgalign's key executives?
Surgalign's management team includes the following people: Mr. Terry M. Rich , Pres, CEO & Director (Age 54, Pay $943.53k) ( LinkedIn Profile )...
What is the stock symbol for Surgalign?
What is the P/E ratio of Surgalign?
Surgalign trades on the NASDAQ under the ticker symbol "SRGA."
Is Surgalign a buy or sell company?
The P/E ratio of Surgalign is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Surgalign pay dividends?
Surgalign has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
What was the loss of Surgalign in 4Q?
Surgalign does not currently pay a dividend.
What is the Vickers top buyer and seller report?
Shares of the medical technology company were down about 14% in Tuesday’s extended trading session. Surgalign (SRGA) posted an adjusted loss of $1.28 per share in 4Q, much higher than analysts' estimates of a loss of $0.32 a share. However, it compared favorably to the year-ago period's loss of $2.72 per share. 4Q revenues declined about 17% year-over-year to $26.2 million but came in marginally ahead of the consensus estimates of $26.1 million. The year-over-year decline in revenues reflects the adverse impact of the COVID-19 pandemic on global elective procedural volumes. Additionally, adjusted EBITDA loss was $7.7 million in 4Q, an improvement from the year-ago period’s loss of $14.3 million, driven by lower operating costs. As for 2021, the company forecasts revenues to grow by 7%-10% year-over-year, which implies a range of $109.1 million-$112.2 million. The company said, “Our guidance assumes that global procedure volumes return to normal levels during the second quarter of 2021.” (See Surgalign Holdings stock analysis on TipRanks) Following the results, BTIG analyst Ryan Zimmerman maintained a Buy rating and a price target of $4 (59.4% upside potential). In a note to investors, the analyst said, “As SRGA transforms into a digital surgery company over the next 12-18 months, we expect a steady product cadence to drive top-line growth combined with the forthcoming FDA [Food and Drug Administration] clearance of ARAI [augmented reality and artificial intelligence] which will complete its first procedures by YE21.” Zimmerman added, “We continue to view risk/reward as favorable although shares may see some modest pressure tomorrow due to the softer guidance and slightly impacted timelines to ARAI.” Overall, SRGA has a Moderate Buy consensus rating based on 2 Buys. The average analyst price target of $4 implies upside potential of over 59% to current levels. Shares are down by 8.7% over the last year. Related News:PAR Technology’s Strong Bookings Drives 4Q Revenue BeatAccel Entertainment’s 4Q Revenues Plunge 39%, Miss EstimatesResonant 4Q Bottom Line Disappoints; Street Remains Bullish More recent articles from Smarter Analyst: WD-40 Bumps Up Quarterly Dividend By 7.5% Village Farms Slips 11% On 4Q Revenue Miss CrowdStrike’s 1Q Revenue Outlook Tops Estimates After 4Q Beat CDW Inks Deal To Buy Amplified IT; Street Says Buy
Do Options Traders Know Something About Surgalign Holdings (SRGA) Stock We Don't?
Daily – Vickers Top Buyers & Sellers for 08/16/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Do insiders buy shares?
Investors need to pay close attention to Surgalign Holdings (SRGA) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Surgalign (SRGA) Stock?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Nasdaq Global Select
Investors need to pay close attention to Surgalign (SRGA) stock based on the movements in the options market la tely.
Environmental, Social, and Governance Rating
The Company uses natural tissues and innovative technologies to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
What are the different grades for stocks?
The Company uses natural tissues and innovative technologies to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes.
How many sectors are there in Zacks?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
